Suchergebnisse

| openaire: EC/H2020/715788/EU//WoCaFi Funding Information: This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant Agreement No 715788). Publisher Copyright: © 2021, The Author(s). ; Cellulose can be dissolved with another biopolymer in a protic ionic liquid and spun into a bicomponent hybrid cellulose fiber using the Ioncell® technology. Inside the hybrid fibers, the biopolymers are mixed at the nanoscale, and the second biopolymer provides the produced hybrid fiber new functional properties that can be fine-tuned by controlling its share in the fiber. In the present work, we present a fast and quantitative thermoanalytical method for the compositional analysis of man-made hybrid cellulose fibers by using thermogravimetric analysis (TGA) in combination with chemometrics. First, we incorporated 0–46 wt.% of lignin or chitosan in the hybrid fibers. Then, we analyzed their thermal decomposition behavior in a TGA device following a simple, one-hour thermal treatment protocol. With an analogy to spectroscopy, we show that the derivative thermogram can be used as a predictor in a multivariate regression model for determining the share of lignin or chitosan in the cellulose hybrid fibers. The method generated cross validation errors in the range 1.5–2.1 wt.% for lignin and chitosan. In addition, we discuss how the multivariate regression outperforms more common modeling methods such as those based on thermogram deconvolution or on linear superposition of reference thermograms. Moreover, we highlight the versatility of this thermoanalytical method—which could be applied to a wide range of composite materials, provided that their components can be thermally resolved—and illustrate it with an additional example on the measurement of polyester content in cellulose and polyester fiber blends. The method could predict the polyester content in the cellulose-polyester fiber blends with a cross validation error of 1.94 wt.% in the range of 0–100 wt.%. Finally, we give a list of recommendations on good experimental and modeling practices for the readers who want to extend the application of this thermoanalytical method to other composite materials. ; Peer reviewed

| openaire: EC/H2020/715788/EU//WoCaFi Funding Information: This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 715788 ). HZ gratefully acknowledges The Finnish Foundation for Technology Promotion , Jenny and Antti Wihuri Foundation , and Niemi Foundation for the encouragement grants. The authors gratefully acknowledge: OtaNano-Nanomicroscopy Center (Aalto-NMC) for the use of XRD instruments; OtaNano-Low Temperature Laboratory (Aalto-LTL) for the use of Raman instrument; Graduate School of Environmental Studies (GSES) of Tohoku University for the use of the EGA-MS and FTIR instruments. YO thanks the NanoBio-ICMG platform (FR 2607) for granting access to the electron microscopy facility. HZ thanks Kanako Yamada and Daichi Ikuta for the support during EGA-MS measurements. Funding Information: This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 715788). HZ gratefully acknowledges The Finnish Foundation for Technology Promotion, Jenny and Antti Wihuri Foundation, and Niemi Foundation for the encouragement grants. The authors gratefully acknowledge: OtaNano-Nanomicroscopy Center (Aalto-NMC) for the use of XRD instruments; OtaNano-Low Temperature Laboratory (Aalto-LTL) for the use of Raman instrument; Graduate School of Environmental Studies (GSES) of Tohoku University for the use of the EGA-MS and FTIR instruments. YO thanks the NanoBio-ICMG platform (FR 2607) for granting access to the electron microscopy facility. HZ thanks Kanako Yamada and Daichi Ikuta for the support during EGA-MS measurements. Publisher Copyright: © 2021 The Author(s) ; Chitosan-cellulose composite fibers spun using a Lyocell technology are characterized by a homogeneous distribution and a close packing of the two biopolymers inside the fibrous matrix. Due to the intimate contact of cellulose and chitosan, synergistic effects can be observed during the pyrolysis of the composite fibers. In this study, the catalytic role of chitosan in altering the cellulose pyrolysis pathway in the composite fibers at moderate treatment temperatures up to 900 °C is confirmed. Analyses of the evolved gases during pyrolysis revealed that chitosan promoted cellulose dehydration and substantially decreased the formation of levoglucosan, explaining the higher char yield. The enhanced dehydration reaction is associated with the formation of intermolecular crosslinks due to the incorporation of nitrogen from chitosan in the resulting carbon structures. Nitrogen could also contribute to the in-plane disorder in the aromatic clusters when the pyrolysis is carried out at 500–700 °C, although the in-plane disorder is less noticeable from 700 to 900 °C. Nevertheless, the size of the aromatic cluster continues to grow when the composite fibers are pyrolyzed in a temperature range of 500–900 °C. ; Peer reviewed

NTRK-Genfusionen sind seltene genetische Alterationen, die tumorentitätenübergreifend vorkommen können. Während sie in den meisten soliden Tumoren nur sehr niederfrequent vorkommen, lassen sie sich in bestimmten Tumoren wie dem infantilen Fibrosarkom, dem kongenitalen mesoblastischen Nephrom und dem sekretorischen Mamma- oder Speicheldrüsenkarzinom jedoch häufig nachweisen. NTRK-Genfusionen bzw. TRK-Fusionsproteine gelten als starke onkogene Treiber. Bei Nachweis von NTRK-Genfusionen können TRK-Inhibitoren unabhängig von der Tumorentität eingesetzt werden. Vertreter sind Entrectinib und Larotrectinib. Bislang ist nur Larotrectinib in der Europäischen Union zugelassen. Für beide wurden Wirksamkeit und Verträglichkeit in Phase-I- und Phase-II-Studien gezeigt. Die Seltenheit der TRK-Fusionstumoren stellt diagnostische und klinische Prozesse vor große Herausforderungen: Einerseits sollen alle Patienten mit TRK-Fusionstumoren identifiziert werden, andererseits sind epidemiologische und histologische Aspekte sowie Ressourcen zu berücksichtigen. Basierend auf diesen Punkten möchten wir einen Diagnosealgorithmus für TRK-Fusionstumoren vorschlagen, außerdem stellen wir aktuelle Daten zu den TRK-Inhibitoren vor. ; NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities. Whereas they are quite rare in most solid tumors they are present at much higher frequencies in certain rare tumors such as infantile fibrosarcoma, congenital mesoblastic nephroma, secretory breast, or salivary gland carcinoma. NTRK gene fusions or TRK fusion proteins are considered strong oncogenic drivers. If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity. So far only larotrectinib is approved in the European Union. Both drugs have been shown to be effective and well tolerated in phase I and phase II studies. The low prevalence of TRK fusion-positive cancers poses challenges for diagnostic and clinical work-flows. On one hand, patients with NTRK gene fusions should be identified; on the other hand, epidemiological, histological, and resource-related aspects have to be taken into account. Based on these premises, we suggest a diagnostic algorithm for TRK fusion cancers and present current data on TRK inhibitors.

NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities. Whereas they are quite rare in most solid tumors they are present at much higher frequencies in certain rare tumors such as infantile fibrosarcoma, congenital mesoblastic nephroma, secretory breast, or salivary gland carcinoma. NTRK gene fusions or TRK fusion proteins are considered strong oncogenic drivers. If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity. So far only larotrectinib is approved in the European Union. Both drugs have been shown to be effective and well tolerated in phase I and phase II studies. The low prevalence of TRK fusion-positive cancers poses challenges for diagnostic and clinical work-flows. On one hand, patients with NTRK gene fusions should be identified; on the other hand, epidemiological, histological, and resource-related aspects have to be taken into account. Based on these premises, we suggest a diagnostic algorithm for TRK fusion cancers and present current data on TRK inhibitors.